News | April 28, 2014

Boston Scientific Begins Trial of Acuity X4 LV Pacing Leads, Reliance 4-Front ICD Leads

The Reliance 4-Front lead is not currently available for sale in the United States.

The Acuity X4 family of leads.

April 28, 2014 — Boston Scientific Corp. has conducted the first implant in the clinical trial of the next-generation Acuity X4 left ventricular (LV) pacing leads and Reliance 4-Front implantable converter defibrillators (ICD) leads. The clinical trial is designed to establish the safety and effectiveness of both lead families and is intended to support U.S. Food and Drug Administration (FDA) approval of these devices.

Acuity X4 LV leads are quadripolar leads engineered to maximize effectiveness and minimize unnecessary patient interventions after implant. The unique 3-D spiral design is intended to minimize floating electrodes, resulting in better electrical performance. In addition, dual-fixation zones and the 2.6 French crossing profile are designed to optimize lead stability and reduce the risk of dislodgement. When an Acuity X4 lead is connected to a Boston Scientific X4 CRT-D, the resulting 17 pacing vector options are designed to improve physicians' ability to manage unexpected complications electronically through programming rather than an invasive lead revision.

The Reliance 4-Front ICD lead is designed for reliability and performance over the long term. The lead maintains the same design principles as the Endotak Reliance lead, yet offers improved handling and maneuverability. Additionally, the Gore coating securely adhered to the defibrillation coils is intended to prevent tissue in-growth and enable both a streamlined implant experience and easier extraction in case of infection.

The first patient enrollments occurred at Wheeling Hospital in Wheeling, W. Va., with Maninder Bedi, M.D., and at Central Baptist Hospital in Lexington, Ky., with Aaron Hesselson, M.D. "The Acuity X4 portfolio allowed me to choose a lead that matched the patient's anatomy," said Hesselson. Likewise, Bedi noted the advantages of the Acuity X4 portfolio for his patient. "This patient may have otherwise had to go for an epicardial lead due to the lack of placement options, but the X4 lead got into several branches of a narrow anatomy that other leads may not have been able to access," said Bedi.

The Navigate X4 trial is a prospective, non-randomized, multicenter, global clinical study designed to support FDA approval. The two principal investigators are Suneet Mittal, M.D., director, electrophysiology, Valley Health System, and Martin C. Burke, D.O., professor of medicine and director, Heart Rhythm Center, University of Chicago Medical Center. The trial is expected to enroll between 1,542 and 2,290 patients at up to 125 centers in the United States, Canada and Israel.  The Acuity X4 and Reliance 4-Front leads will be connected to commercially available Boston Scientific X4 CRT-D devices.

The Acuity X4 LV pacing leads and Reliance 4-Front defibrillator leads are CE marked. In the United States, they are investigational devices and not available for sale.

For more information: www.bostonscientific.com

Related Content

CHLA/USC Team Designs Novel Micropacemaker

Model of the human heart with microprocessor located in the pericardial sac and attached to the left ventricle. Graphic courtesy of Business Wire.

News | Pacemakers | June 29, 2018
Investigators at Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) have...
Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block
News | Pacemakers | May 24, 2018
Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist...
Novel Mechanical Sensor in Medtronic Micra Transcatheter Pacing System Detects Atrial Contractions, Restores AV Synchrony
News | Pacemakers | May 24, 2018
New clinical study results demonstrate that an investigational algorithm, utilizing the accelerometer signal in the...
The Boston Scientific Essentio MRI-safe pacemaker.

The Boston Scientific Essentio MRI-safe pacemaker. It is common for pacemaker patients to need magnetic resonance imaging (MRI), which has not previously been possible because the magnetic fields could damage older devices. All pacemaker vendors now have FDA-cleared MRI compatible pacemakers. 

Feature | Pacemakers | February 13, 2018 | Dave Fornell
There have been several advancements in pacemaker technologies over the past few years.
Mexican Doctors Safely Reuse Donated Pacemakers After Sterilization

Mexican government reports conclude more than half of the population does not have access to social security or private insurance that covers a pacemaker implant, and 44 percent live in poverty. Recycling donated, explanted pacemakers offers a new option for these patients.

News | Pacemakers | November 10, 2017
Mexican doctors have safely reused donated pacemakers after sterilization, shows a study presented at the 30th Mexican...
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers | June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
Videos | Pacemakers | May 23, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
micra leadless pacemaker
Feature | Pacemakers | May 16, 2017
May 16, 2017 - The preliminary results for the Medtronic Micra Transcatheter Pacing System (TPS) Post-Approval Regist
Videos | Pacemakers | May 16, 2017
This video, provided by Medtronic, demonstrates the implantation of Micra transcatheter pacing system (TPS).
closed loop stimulation, DDD-CLS, ACC17, SPAIN trial
Feature | Pacemakers | March 22, 2017
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing pro
Overlay Init